V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Intellia Therapeutics Executive Compensation (FY25)

NTLA · Executive and director compensation, fiscal 2025 only

The paid brief on Intellia Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 20, 2026Latest filing (8-K): June 10, 2026
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Intellia Therapeutics brief$1,500Get the executive brief
231 figures on this page: 223 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
John Leonard
Latest say-on-pay support
=
June 9, 2026
Chief executive pay ratio
◇
To the median employee

More on Intellia Therapeutics

Five data products on this company. Each one is requested through the developer setup page.

Frequently asked questions

Answers drawn from the data on this page.
Who is Intellia Therapeutics' chief executive and what were they paid?
Total compensation for John Leonard, President, Chief Executive Officer, came to $5,063,899 in fiscal 2025.
What was Intellia Therapeutics' say-on-pay result?
The say-on-pay proposal drew 76.4% of votes cast for or against in favor at the meeting held June 9, 2026 for fiscal 2025.
Which companies are in Intellia Therapeutics' peer group?
Companies named in the disclosed peer group include Arrowhead Pharmaceuticals, Inc., Beam Therapeutics Inc., BridgeBio Pharma, Inc., CRISPR Therapeutics AG and Denali Therapeutics Inc., among others.
What is Intellia Therapeutics' chief executive pay ratio?
The company reported a chief executive pay ratio of 17:1 for fiscal 2025, against median employee compensation of $301,044.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Leonard
President, Chief Executive Officer
◇◇◇◇——◇◇
Edward Dulac
Executive Vice President, Chief Financial Officer and Treasurer
◇◇◇◇——◇◇
David Lebwohl
Executive Vice President, Chief Medical Officer
◇◇◇◇——◇◇
James Basta
Executive Vice President, General Counsel and Corporate Secretary
◇◇◇◇——◇◇
Birgit Schultes
Executive Vice President, Chief Scientific Officer
◇◇◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Birgit SchultesOPTION◇——◇—◇◇
Birgit SchultesPSU◇◇◇—◇—◇
Birgit SchultesRSU◇——◇——◇
David LebwohlRSU◇——◇——◇
David LebwohlPSU◇◇◇—◇—◇
David LebwohlOPTION◇——◇—◇◇
Edward J. Dulac IIIPSU◇◇◇—◇—◇
Edward J. Dulac IIIRSU◇——◇——◇
Edward J. Dulac IIIOPTION◇——◇—◇◇
James BastaPSU◇◇◇—◇—◇
James BastaOPTION◇——◇—◇◇
James BastaRSU◇——◇——◇
John M. LeonardOPTION◇——◇—◇◇
John M. LeonardPSU◇◇◇—◇—◇
John M. LeonardRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Birgit SchultesOption◇—◇2/28/2034
Option◇—◇2/28/2033
RSU◇◇——
PSU◇◇——
Option◇—◇2/28/2035
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
David LebwohlOption◇—◇2/28/2035
Option◇—◇2/28/2033
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/28/2034
RSU◇◇——
PSU◇◇——
PSU◇◇——
James BastaPSU◇◇——
PSU◇◇——
Option◇—◇2/28/2034
RSU◇◇——
Option◇—◇2/28/2035
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/28/2033
John LeonardPSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/28/2033
Option◇—◇2/28/2034
Option◇—◇2/28/2035
Edward DulacPSU◇◇——
Option◇—◇7/21/2034
Option◇—◇2/28/2035
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Frank Verwiel
◇◇◇———◇
William Chase
◇◇◇———◇
Brian Goff
◇◇◇———◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Arrowhead Pharmaceuticals, Inc. ARWR
  • Beam Therapeutics Inc. BEAM
  • BridgeBio Pharma, Inc. BBIO
  • CRISPR Therapeutics AG CRSP
  • Denali Therapeutics Inc. DNLI
  • Editas Medicine, Inc. EDIT
  • IDEAYA Biosciences, Inc. IDYA
  • ImmunityBio, Inc. IBRX
  • Immunovant, Inc. IMVT
  • Iovance Biotherapeutics, Inc. IOVA
  • Madrigal Pharmaceuticals, Inc. MDGL
  • Prime Medicine, Inc. PRME
  • Relay Therapeutics, Inc. RLAY
  • Rocket Pharmaceuticals, Inc. RCKT
  • Sana Biotechnology, Inc. SANA
  • Vaxcyte, Inc. PCVX
  • Verve Therapeutics, Inc. VERV
  • Vir Biotechnology, Inc. VIR
  • Xencor, Inc. XNCR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 9, 2026=◇◇◇
2024June 11, 2025=◇◇◇
2023June 12, 2024=◇◇◇
2022June 14, 2023=◇◇◇
2021June 14, 2022=◇◇◇
2020June 23, 2021=◇◇◇
2019June 18, 2020=◇◇◇
2018May 21, 2019=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Intellia Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Intellia Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Intellia Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Intellia Therapeutics' disclosed peer group is defensible, who names Intellia Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
231 figures on this page: 223 cited to the filing that reported them, 8 calculated from figures it prints.
223 cited to the filing
8 calculated from the filing

Documents cited

  1. 0001193125-26-265934
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-197283
    2025 Summary Compensation Table · Director Compensation · Grants of Plan-Based Awards
  3. 0000950170-25-085479
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000950170-24-073116
  5. 0000950170-23-028611
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000950170-22-011691
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001564590-21-034323
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001564590-20-029961
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001193125-19-154097
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Intellia Therapeutics executive compensation, FY2025.” https://intel.velarion.ai/comp/NTLA (accessed 2026).
Short form: data: Velarion

The paid brief for Intellia Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Intellia Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Intellia Therapeutics discloses

The companies named in NTLA's own disclosed peer group.

Arrowhead Pharmaceuticals, Inc.Beam Therapeutics Inc.BridgeBio Pharma, Inc.CRISPR Therapeutics AGDenali Therapeutics Inc.Editas Medicine, Inc.IDEAYA Biosciences, Inc.ImmunityBio, Inc.Immunovant, Inc.Iovance Biotherapeutics, Inc.Madrigal Pharmaceuticals, Inc.Prime Medicine, Inc.Relay Therapeutics, Inc.Rocket Pharmaceuticals, Inc.Sana Biotechnology, Inc.Vaxcyte, Inc.Verve Therapeutics, Inc.Vir Biotechnology, Inc.Xencor, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy